Literature DB >> 17582527

Functional capacity and changes in the neurohormonal and cytokine status after long-term CRT in heart failure patients.

M Seifert1, M Schlegl, W Hoersch, E Fleck, A Doelger, M Stockburger, C Butter.   

Abstract

BACKGROUND: This study investigated the effects of long-term cardiac resynchronization therapy (CRT) on the neurohormonal and cytokines levels in CHF patients and its correlation with changes in functional capacity (peak VO(2) and VO(2) AT) and left ventricular function (LVEF).
METHODS: Brain natriuretic peptide (BNP), norepinephrine (NE), tumor necrosis factor alpha (TNF alpha), tumor necrosis factor alpha receptor 1 (TNF alpha R1) and interleukin 6 (IL-6) were collected from 22 patients of the PATH-CHF II study (LVEF< or =30%, NYHA II-IV and QRS> or =120 ms) at baseline and at the 12-month follow-up. Peak VO(2), VO(2) AT and LVEF were recorded. All patients were implanted with a CRT device using atrioventricular sequential left ventricular pacing.
RESULTS: CRT led to a significant improvement of peak VO(2) (from 13+/-2.4 ml/kg/min to 14.8+/-2.8 ml/kg/min, p<0.05) and VO(2) AT (from 9+/-2 ml/kg/min to 10.1+/-1.9 ml/kg/min, p<0.05). LVEF increased significantly from 22.2+/-6.2% at baseline to 32+/-10.1% at 12-month follow-up (p<0.05). A significant reduction of BNP (from 332.9+/-295.2 to 193.4+/-253 pg/ml, p=0.049) and NE (410.6+/-306.0 to 274.4+/-174.3 ng/l, p=0.027) was also observed with CRT.
CONCLUSION: Long-term CRT is associated with a significant decrease of BNP and NE levels and a significant improvement in functional capacity and LVEF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17582527     DOI: 10.1016/j.ijcard.2007.04.069

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

1.  Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in heart failure.

Authors:  Ying-Xue Dong; John C Burnett; Horng H Chen; Sharon Sandberg; Yan-Zhong Yang; Yanhua Zhang; Peng-Sheng Chen; Yong-Mei Cha
Journal:  J Interv Card Electrophysiol       Date:  2011-02-19       Impact factor: 1.900

2.  Association of BNP and Troponin Levels with Outcome among Cardiac Resynchronization Therapy Recipients.

Authors:  Alaa A Shalaby; William T Abraham; Gregg C Fonarow; Malcolm M Bersohn; John Gorcsan; Li-Yin Lee; Jasmina Halilovic; Samir Saba; Alan Maisel; Jagmeet P Singh; Ali Sonel; Alan Kadish
Journal:  Pacing Clin Electrophysiol       Date:  2015-03-30       Impact factor: 1.976

3.  Inflammatory activation following interruption of long-term cardiac resynchronization therapy.

Authors:  Andrzej Rubaj; Piotr Ruciński; Krzysztof Oleszczak; Michał K Trojnar; Maciej Wójcik; Andrzej Wysokiński; Andrzej Kutarski
Journal:  Heart Vessels       Date:  2012-12-16       Impact factor: 2.037

4.  Cardiac resynchronization therapy upregulates cardiac autonomic control.

Authors:  Yong-Mei Cha; Jae Oh; Chinami Miyazaki; David L Hayes; Robert F Rea; Win-Kuang Shen; Samuel J Asirvatham; Brad J Kemp; David O Hodge; Peng-Sheng Chen; Panithaya Chareonthaitawee
Journal:  J Cardiovasc Electrophysiol       Date:  2008-05-09

5.  The partial pressure of resting end-tidal carbon dioxide predicts major cardiac events in patients with systolic heart failure.

Authors:  Ross Arena; Jonathan Myers; Joshua Abella; Sherry Pinkstaff; Peter Brubaker; Brian Moore; Dalane Kitzman; Mary Ann Peberdy; Daniel Bensimhon; Paul Chase; Marco Guazzi
Journal:  Am Heart J       Date:  2008-08-27       Impact factor: 4.749

6.  High sensitivity C-reactive protein and cardfiac resynchronization therapy in patients with advanced heart failure.

Authors:  Chi Cai; Wei Hua; Li-Gang Ding; Jing Wang; Ke-Ping Chen; Xin-Wei Yang; Zhi-Min Liu; Shu Zhang
Journal:  J Geriatr Cardiol       Date:  2014-12       Impact factor: 3.327

7.  Prediction of clinical outcome in patients treated with cardiac resynchronization therapy - the role of NT-ProBNP and a combined response score.

Authors:  Z Bakos; N C Chatterjee; C Reitan; J P Singh; R Borgquist
Journal:  BMC Cardiovasc Disord       Date:  2018-04-24       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.